Patient P-02433
Therapy response
Favorable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
65%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S07
- Day 122 GI-04 recommended — GI Support Protocol GI-04
- Day 123 Patient accepted — Started GI-04 in the companion
- Day 131 GI symptom burden −23% vs expected — GI Support Protocol GI-04
- Day 135 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 137 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 135.
Primary contributors, last 14 days
- Nutritional resilience-16
- GI instability+13
- Treatment adherence-12
- Inflammatory activity-3
What helped?
- GI Support Protocol GI-04Day 122Result: symptom burden −23%
LIFE OS recommendation
Monitoring Escalation ME-01
77%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓40
- BloodInflammatory load index 46
- WearableHRV 17 ms, trending down
- Autonomic recovery ↓40
- Wearable1,885 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 39/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 6.6 h
- Steps
- 2,118
- Resting HR
- 69 bpm
Daily log: GI score 51, nutritional resilience 39, adherence 67.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02334 | 51% | S04 | GI-04 | improved | 66 |
| P-02265 | 49% | S07 | GI-04 | no change | 67 |
| P-02530 | 49% | S07 | — | — | 67 |
| P-02084 | 47% | S11 | GI-04 | no change | 58 |
| P-02240 | 44% | S20 | GI-04 | improved | 57 |
| P-02078 | 42% | S04 | — | — | 56 |
| P-02160 | 42% | S03 | — | — | 45 |
| P-02054 | 41% | S01 | CR-01 | improved | 57 |
| P-02591 | 41% | S13 | — | — | 68 |
| P-02631 | 41% | S17 | — | — | 58 |
| P-02029 | 40% | S18 | — | — | 56 |
| P-02136 | 40% | S10 | — | — | 63 |